Benzothiazole Derivatives Endowed with Antiproliferative Activity in Paraganglioma and Pancreatic Cancer Cells: Structure–Activity Relationship Studies and Target Prediction Analysis
暂无分享,去创建一个
A. Cama | Mariangela Agamennone | B. De Filippis | A. Ammazzalorso | M. Fantacuzzi | L. Giampietro | C. Maccallini | R. Amoroso | L. De Lellis | Rocío Recio | Rosalba Florio | Inmaculada Fernández | N. Moreno
[1] O. Nicolotti,et al. PLATO: A Predictive Drug Discovery Web Platform for Efficient Target Fishing and Bioactivity Profiling of Small Molecules , 2022, International journal of molecular sciences.
[2] Domenico Alberga,et al. Quantitative Polypharmacology Profiling Based on a Multifingerprint Similarity Predictive Approach , 2021, J. Chem. Inf. Model..
[3] P. Tokarz,et al. SENP Proteases as Potential Targets for Cancer Therapy , 2021, Cancers.
[4] B. Shainyan,et al. Modern Approaches to the Synthesis and Transformations of Practically Valuable Benzothiazole Derivatives , 2021, Molecules.
[5] G. Schneider,et al. The SUMO pathway in pancreatic cancer: insights and inhibition , 2020, British Journal of Cancer.
[6] S. Carradori,et al. 2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationships. , 2020, European journal of medicinal chemistry.
[7] Dongsheng Cao,et al. A combinatorial target screening strategy for deorphaning macromolecular targets of natural product. , 2020, European journal of medicinal chemistry.
[8] Yaxue Zhao,et al. Benzothiophene-2-carboxamide derivatives as SENPs inhibitors with selectivity within SENPs family. , 2020, European journal of medicinal chemistry.
[9] Arda B. Celen,et al. Sumoylation on its 25th Anniversary: Mechanisms, Pathology and Emerging Concepts. , 2020, The FEBS journal.
[10] A. Lavecchia,et al. Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies , 2020, ACS medicinal chemistry letters.
[11] Suwen Zhao,et al. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures , 2020, Cell.
[12] C. Supuran,et al. Benzothiazole derivatives as anticancer agents , 2019, Journal of enzyme inhibition and medicinal chemistry.
[13] N. Tinari,et al. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer , 2019, Cancers.
[14] A. Cama,et al. Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. , 2019, Bioorganic & medicinal chemistry letters.
[15] H. Ovaa,et al. Chemical Tools and Biochemical Assays for SUMO Specific Proteases (SENPs) , 2019, ACS chemical biology.
[16] D. Alberga,et al. Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search † , 2019, Molecules.
[17] Olivier Michielin,et al. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..
[18] A. Krivokuca,et al. The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? , 2019, Front. Pharmacol..
[19] Andrea Volkamer,et al. Advances and Challenges in Computational Target Prediction , 2019, J. Chem. Inf. Model..
[20] Daniela Trisciuzzi,et al. A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL) , 2018, J. Chem. Inf. Model..
[21] Jean-Louis Reymond,et al. Polypharmacology Browser PPB2: Target Prediction Combining Nearest Neighbors with Machine Learning , 2018, J. Chem. Inf. Model..
[22] A. Cama,et al. Cytotoxic effect of a family of peroxisome proliferator‐activated receptor antagonists in colorectal and pancreatic cancer cell lines , 2017, Chemical biology & drug design.
[23] R. Mariani-Costantini,et al. Effects of PPARα inhibition in head and neck paraganglioma cells , 2017, PloS one.
[24] A. Giordano,et al. PPARα Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells , 2017, Journal of cellular physiology.
[25] Xia Wang,et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database , 2017, Nucleic Acids Res..
[26] A. Pae,et al. Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad‐Spectrum Antiproliferative Activity , 2016, ChemMedChem.
[27] M. Wiesmann,et al. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite , 2015, Xenobiotica; the fate of foreign compounds in biological systems.
[28] Rangappa S. Keri,et al. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. , 2015, European journal of medicinal chemistry.
[29] D. Reverter,et al. Structural insights into the SENP6 Loop1 structure in complex with SUMO2 , 2014, Protein science : a publication of the Protein Society.
[30] L. Coussens,et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells , 2013, Oncoimmunology.
[31] Xiaofeng Liu,et al. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method , 2013, Bioinform..
[32] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[33] H. Rajak,et al. Medicinal significance of benzothiazole scaffold: an insight view , 2013, Journal of enzyme inhibition and medicinal chemistry.
[34] P. Linciano,et al. Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα. , 2012, European journal of medicinal chemistry.
[35] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[36] A. Westwell,et al. 2-Arylbenzothiazole as a privileged scaffold in drug discovery. , 2009, Current medicinal chemistry.
[37] Thomas A. Halgren,et al. Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..
[38] Stefan Günther,et al. SuperPred: drug classification and target prediction , 2008, Nucleic Acids Res..
[39] K. Mackie,et al. Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.
[40] H. Friess,et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain , 2008, International journal of cancer.
[41] Tom Halgren,et al. New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.
[42] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[43] A. Westwell,et al. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. , 2004, Current medicinal chemistry.
[44] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[45] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[46] M. Stevens,et al. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. , 2001, Current medicinal chemistry.
[47] G. Kouraklis,et al. Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer? , 2022, In Vivo.
[48] Adrià Cereto-Massagué,et al. Tools for in silico target fishing. , 2015, Methods.